Publication | Closed Access

Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study

Acute Lung InjuryInflammationInflammatory Lung DiseaseAdvanced Lung DiseaseLung InflammationNeutrophil Elastase InhibitorPhase Iv StudySepsisInflammatory MarkerPulmonary PharmacologyMedicineEmergency Medicine